We are privileged to share the acknowledgment that APICES has received in the recent publication titled: “Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy”, a study in which APICES has participated in study design, setup, coordination and project management, monitoring, statistical analysis and writing of a draft manuscript.
This means to all APICES team an extra motivation in order to give continuity to the implication we have in every project in which we collaborate. APICES is proud of the recognition of our work and we want to thank Dr Grande and SOGUG for the opportunity he has given to APICES to appear in the publication acknowledgments, and congratulate them and the rest of collaborating investigators for their project success. This study evaluates the efficacy and safety of sunitinib as a pure second-line treatment in patients with metastatic renal cell carcinomawho have progressed to first-line immune checkpoint inhibitor based therapies.
You can find the publication in the following link:
https://www.sciencedirect.com/science/article/pii/S2059702922000813
